{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:05:48Z","timestamp":1769709948156,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) often coexists with pulmonary hypertension (PH), leading to exacerbated morbidity and mortality. Conventional treatments focus on bronchodilation, anti-inflammatory agents, and vasodilators, emphasizing the need for novel interventions. Atorvastatin and azithromycin have pleiotropic properties that may benefit COPD with concomitant PH. However, the combined impact of these medications on lung and right heart function in this patient population remains underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study involving 229 stable COPD patients with concomitant PH assessed the effects of atorvastatin combined with azithromycin. Patients were divided into atorvastatin monotherapy and atorvastatin plus azithromycin combination therapy groups and underwent a 6-month treatment period. Blood testing, pulmonary function testing, and echocardiographic assessment of right heart function were conducted before and after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The combination therapy group exhibited significant improvements in blood gas indicators (mean PaO\n                      <jats:sub>2<\/jats:sub>\n                      increase: 1.22\u202fkPa, 95% CI: 0.82\u20131.62\u202fkPa,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), lung function (mean FEV1 increase: 0.18\u202fL, 95% CI: 0.08\u20130.28\u202fL,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), right heart function (mean PAPs reduction: 8.0\u202fmmHg, 95% CI: 7.0\u20139.0\u202fmmHg,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), respiratory distress, and daily living ability compared to the monotherapy group. Positive correlations were observed between improvements in pulmonary function and daily living ability. The combination therapy resulted in a significantly higher total effective rate (84.48% vs. 72.73%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.042) compared to the monotherapy group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This retrospective study suggests potential associations between combination therapy with atorvastatin and azithromycin and improvements in functional outcomes in COPD patients with concomitant PH. These findings warrant prospective validation in randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1667773","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:41:42Z","timestamp":1769668902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of atorvastatin combined with azithromycin on lung function and right heart function in COPD patients with concomitant pulmonary hypertension"],"prefix":"10.3389","volume":"12","author":[{"given":"Weiwei","family":"Que","sequence":"first","affiliation":[{"name":"Pulmonary and Critical Care Medicine, The First Hospital of Longyan Affiliated to Fujian Medical University","place":["Longyan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, The First Hospital of Longyan Affiliated to Fujian Medical University","place":["Longyan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The First Hospital of Longyan Affiliated to Fujian Medical University","place":["Longyan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youtang","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The First Hospital of Longyan Affiliated to Fujian Medical University","place":["Longyan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyi","family":"Ma","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, The First Hospital of Longyan Affiliated to Fujian Medical University","place":["Longyan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","article-title":"Chronic obstructive pulmonary disease","volume":"399","author":"Christenson","year":"2022","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pulmoe.2019.10.006","article-title":"Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art","volume":"26","author":"Corlateanu","year":"2020","journal-title":"Pulmonology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","article-title":"Pulmonary hypertension","volume":"10","author":"Mocumbi","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"Itc49","DOI":"10.7326\/AITC202104200","article-title":"Pulmonary hypertension","volume":"174","author":"Poch","year":"2021","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.chest.2023.03.029","article-title":"Evaluation and management of chronic thromboembolic pulmonary hypertension","volume":"164","author":"Yang","year":"2023","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccm.2020.06.007","article-title":"Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations","volume":"41","author":"Ritchie","year":"2020","journal-title":"Clin Chest Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e21828","DOI":"10.7759\/cureus.21828","article-title":"Evaluation of pulmonary hypertension in chronic obstructive pulmonary disease","volume":"14","author":"Aurangabadkar","year":"2022","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/bph.14979","article-title":"Pulmonary hypertension in chronic obstructive pulmonary disease","volume":"178","author":"Gredic","year":"2021","journal-title":"Br J Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S2213-2600(23)00259-X","article-title":"Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management","volume":"11","author":"Olsson","year":"2023","journal-title":"Lancet Respir Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/MCP.0000000000000984","article-title":"Pulmonary hypertension in interstitial lung disease and in chronic obstructive pulmonary disease: different entities?","volume":"29","author":"Piccari","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1164\/rccm.202306-1066ST","article-title":"Pulmonary rehabilitation for adults with chronic respiratory disease: an official American Thoracic Society clinical practice guideline","volume":"208","author":"Rochester","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S2213-2600(21)00506-3","article-title":"Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment","volume":"10","author":"Yang","year":"2022","journal-title":"Lancet Respir Med"},{"key":"ref13","first-page":"689","article-title":"Research progress of inflammatory factors in chronic obstructive pulmonary disease with pulmonary hypertension at high altitude","volume":"29","author":"Huang","year":"2023","journal-title":"Altern Ther Health Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3390\/ijms22041828","article-title":"Atorvastatin inhibits endothelial PAI-1-mediated monocyte migration and alleviates radiation-induced enteropathy","volume":"22","author":"Kwak","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"115228","DOI":"10.1016\/j.biopha.2023.115228","article-title":"Atorvastatin rescues vascular endothelial injury in hypertension by WWP2-mediated ubiquitination and degradation of ATP5A","volume":"166","author":"Yin","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"9247285","DOI":"10.1155\/2021\/9247285","article-title":"Sphingosine kinase 1 plays an important role in atorvastatin-mediated anti-inflammatory effect against acute lung injury","volume":"2021","author":"Wu","year":"2021","journal-title":"Mediat Inflamm"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e24427","DOI":"10.1002\/jcla.24427","article-title":"Mechanism of action, resistance, synergism, and clinical implications of azithromycin","volume":"36","author":"Heidary","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/10499091231167879","article-title":"Validation of a novel clinical Dyspnea scale - a retrospective pilot study","volume":"41","author":"Kalluri","year":"2024","journal-title":"Am J Hosp Palliat Care"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/11038128.2019.1689291","article-title":"Measurement properties of performance-based instruments to assess mental function during activity and participation in traumatic brain injury: a systematic review","volume":"27","author":"Kristensen","year":"2020","journal-title":"Scand J Occup Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-med-080919-112707","article-title":"Advances in chronic obstructive pulmonary disease","volume":"72","author":"Ferrera","year":"2021","journal-title":"Annu Rev Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"Itc17","DOI":"10.7326\/AITC202008040","article-title":"Chronic obstructive pulmonary disease","volume":"173","author":"Labaki","year":"2020","journal-title":"Ann Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12890-023-02444-1","article-title":"The effect of azithromycin on sputum inflammatory markers in bronchiectasis","volume":"23","author":"Terpstra","year":"2023","journal-title":"BMC Pulm Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.14573\/altex.2001271","article-title":"Azithromycin has lung barrier protective effects in a cell model mimicking ventilator-induced lung injury","volume":"37","author":"Joelsson","year":"2020","journal-title":"ALTEX"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.healun.2020.09.006","article-title":"Azithromycin prophylaxis after lung transplantation is associated with improved overall survival","volume":"39","author":"Li","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40168-023-01460-x","article-title":"Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease","volume":"11","author":"Abotsi","year":"2023","journal-title":"Microbiome"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"112739","DOI":"10.1016\/j.ejmech.2020.112739","article-title":"Azithromycin: the first broad-spectrum therapeutic","volume":"207","author":"Firth","year":"2020","journal-title":"Eur J Med Chem"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jcf.2022.02.015","article-title":"Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas","volume":"21","author":"Pittman","year":"2022","journal-title":"J Cyst Fibros"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.12669\/pjms.38.8.6283","article-title":"Effects of azithromycin on serum inflammatory factors and T lymphocyte subsets in patients with gynecological mycoplasma infection","volume":"38","author":"She","year":"2022","journal-title":"Pak J Med Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"174191","DOI":"10.1016\/j.ejphar.2021.174191","article-title":"Azithromycin: immunomodulatory and antiviral properties for SARS-CoV-2 infection","volume":"905","author":"Khezri","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"574425","DOI":"10.3389\/fimmu.2021.574425","article-title":"Immunomodulatory effects of azithromycin revisited: potential applications to COVID-19","volume":"12","author":"Venditto","year":"2021","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"966060","DOI":"10.3389\/fonc.2023.966060","article-title":"Immunomodulatory role of azithromycin: potential applications to radiation-induced lung injury","volume":"13","author":"Yan","year":"2023","journal-title":"Front Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1667773\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:41:43Z","timestamp":1769668903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1667773\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":33,"alternative-id":["10.3389\/fmed.2025.1667773"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1667773","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1667773"}}